EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022

Ashish C Shrestha iD, Emma Field, Dharshi Thangarajah, Ross Andrews, Robert S Ware, Stephen B Lambert iD

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.70007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Ashish C Shrestha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Queensland Public Health and Scientific Services, Queensland Health, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Vaccine Efficacy, Hospitalization. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National University Master of Philosophy (Applied Epidemiology) Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2022, publicly funded influenza vaccine was made available to all residents of Queensland, Australia. This study compared influenza epidemiology in 2022 with previous years (2017–2021) and estimated influenza vaccine effectiveness (VE) during 2022.

Methods

The study involved a descriptive analysis of influenza notifications and a case–control study to estimate VE. Cases were notifications of laboratory‐confirmed influenza, and controls were individuals who were test negative for COVID‐19. Cases and controls were matched on age, postcode and specimen collection date. VE against hospitalisation was investigated by matching hospitalised cases to controls. Conditional logistic regression models were adjusted for sex.

Results

In 2022, Queensland experienced an early influenza season onset (April–May) and high case numbers ( n = 45,311), compared to the previous 5 years (annual average: 29,364) and 2020–2021 (2020:6047; 2021:301) during the COVID‐19 pandemic. Adjusted VE (VE ad j) against laboratory‐confirmed influenza was 39% (95% confidence interval [CI]: 37–41), highest for children aged 30 months to < 5 years (61%, 95% CI: 49–70) and lowest for adults aged ≥ 65 years (24%, 95% CI: 17–30). VE adj against influenza‐associated hospitalisation was 54% (95% CI: 48–59). Among children < 9 years of age, VE adj against laboratory‐confirmed influenza (55%, 95% CI: 49–61) and hospitalisation (67%, 95% CI: 39–82) was higher in those who received a complete dose schedule.

Conclusion

In Queensland, the 2022 influenza season started earlier than the previous 5 years. VE against influenza notifications varied across age groups. VE estimates against influenza‐associated hospitalisation were higher than those against laboratory‐confirmed influenza.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza VaccinesVaccine EfficacyHospitalizationHumansQueenslandMiddle AgedChild, PreschoolMaleFemaleChildAdultAgedInfantAdolescentCase-Control StudiesYoung AdultCOVID-19VaccinationSARS-CoV-2SeasonsAged, 80 and over

Stichwörter der Autor:innen

AustraliaQueenslandfluinfluenzainfluenza vaccinevaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Queensland Public Health and Scientific Services, Queensland Health, Brisbane, Queensland, Australia.
  • National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.
  • Department of Health and Aged Care, Canberra, Australian Capital Territory, Australia.
  • Griffith Biostatistics Unit, Griffith University, Brisbane, Queensland, Australia.
  • National Centre for Immunisation Research and Surveillance, Sydney, New South Wales, Australia.

ORCID-Profile: Ashish C Shrestha, Stephen B Lambert

Förderung

  • Australian National University Master of Philosophy (Applied Epidemiology) Scholarship

Zitieren

APA

Shrestha, A. C., Field, E., Thangarajah, D., Andrews, R., Ware, R. S., & Lambert, S. B. (2024). Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70007

Vancouver

Shrestha AC, Field E, Thangarajah D, Andrews R, Ware RS, Lambert SB. Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70007

BibTeX
@article{Shrestha2024,
  author = {Shrestha, Ashish C and Field, Emma and Thangarajah, Dharshi and Andrews, Ross and Ware, Robert S and Lambert, Stephen B},
  title = {Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.70007}
}
Kostenlos starten →